JPRN-UMIN000001002招募中1 期
Phase I study using BK-UM against HB-EGF for patients with advanced or recurrent ovarian cancer - Phase I study using BK-UM for patients with recurrent ovarian cancer
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old(—)
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. exclude the patients who have serious illness or suspect to have serious illness menthioned below (1)exclude the patients who have ischemic heart diseases ro arrythmia to give medical treatment (2)exclude the patients who have less than 50% in ejection fraction using echocardiogram (3)exclude the patients who have cardiac dysfunction as grade III or IV of NYHA or have cardiac infarction within 6 months (4)exclude the patients who have liver schirosis beyond medical control (5)exclude the patients who need the oxigen supplement because of pulmonary intestitial pneumonitis or fiibrosis (6) exclude the patients who need or do medical treatment for mental diseases (7) exclude the patients who have serious diabetes beyond medical control (8) exclude the patients who have ileus or subileus (9)exclude the patients who have serious infection beyond medical control 2. exclude the patients who have previously had seriuos allergic sensitivity 3. exclude the patients who have pregnancy or nursing or have possiblity to be pregnant 4. exclude the patients who have previoursly had some anti-serum 5. exclude the patients who have serious other malignancy influenced on their survival 6. exclude the patients who have the agent used in other clinical trial within 4 weeks. 7. exclude the patients who are recognized as inadequate patients by doctors wth resposibility in this clinical trial
研究者
相似试验
已完成
2 期
Phase II Trial of BK-UM against HB-EGF in combination with Gemcitabine in Patients with advanced or recurrent ovarian cancerPatients with advanced or recurrent ovarian cancer (include fallopian tube cancer and peritoneal cancer)JPRN-UMIN000009923Osaka University64
已完成
1 期
Phase I/II study of HB-EGF-specific inhibitor BK-UM plus weekly paclitaxel therapy in gastric cancer with peritoneal metastasis after failure of first line treatment.advanced and/or recurrent gastric cancer with peritoneal metastasisJPRN-UMIN000015812Kyushu University Hospital42
尚未招募
2 期
Evaluation of BCG as potential therapy for COVID-19CTRI/2020/05/025013Medical Education and Drugs Department
尚未招募
2 期
To study the effect of kashaya and snehana and swedana at chest region in the treatment of bronchial asthmaCTRI/2021/08/036014DrJayanti Dutta
已完成
1 期
Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA PropellantChronic Obstructive Pulmonary DiseaseNCT05477108AstraZeneca108
